Additional file 1 of Genetic effect of metformin use on risk of cancers: evidence from Mendelian randomization analysis

Additional file 1. Table S1: SNPs associated with metformin use, which performed as instrumental variants (IVs) in two-sample MR analysis. Table S2: The genetic effect obtained from MVMR analysis. TT: total testosterone levels. Fig. S1: Scatter plots and funnel plots of metformin use on HER-positive breast cancer. A Scatter plots of the genetic association between metformin use and HER-positive breast cancer. The genetic predicted metformin use is associated with a lower risk of HER-positive breast cancer. The slope of each line shows the estimated causal effect of metformin use on HER-positive breast cancer for each approach. B Funnel plots showing the statistical association between metformin use and the risk of HER-positive breast cancer. Fig. S2: Leave-one-out analysis and Forest plots results. A Leave-one-out analysis of sensitivity test. After one by one eliminating the IVs, calculate the MR outcomes for the remaining IVs. B Forest plot of the causal effects of metformin use associated SNPs on HER-positive breast cancer. B Showed the Mendelian randomization estimated effects sizes for metformin use on HER-positive breast cancer. Fig. S3: Leave-one-out analysis result of metformin use on total testosterone levels. Fig. S4: Leave-one-out analysis result of total testosterone levels on HER-positive breast cancer. Fig. S5: Scatter plot of metformin use on total testosterone levels. Fig. S6: Scatter plot of total testosterone levels on HER-positive breast cancer. Fig. S7: Forest plot of metformin use on total testosterone levels. Fig. S8: Forest plot of total testosterone levels on HER-positive breast cancer. Fig. S9: Funnel plot of metformin use on total testosterone levels. Fig. S10: Funnel plot of total testosterone levels on HER-positive breast cancer